Hsbc Holdings PLC Viridian Therapeutics, Inc.\De Transaction History
Hsbc Holdings PLC
- $159 Billion
- Q1 2025
A detailed history of Hsbc Holdings PLC transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Hsbc Holdings PLC holds 39,452 shares of VRDN stock, worth $549,171. This represents 0.0% of its overall portfolio holdings.
Number of Shares
39,452Holding current value
$549,171% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding VRDN
# of Institutions
189Shares Held
79.6MCall Options Held
92.2KPut Options Held
55.2K-
Deep Track Capital, LP Greenwich, CT5.38MShares$74.9 Million2.54% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$66.4 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ4.7MShares$65.4 Million5.34% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.56MShares$63.5 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$54 Million12.64% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $555M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...